Start here if you're new
what it is
It is a pre-revenue biotech trying to turn fibroblast cells into treatments for wounds, MS, spine disease, psoriasis, cancer, and aging.
how it gets paid
Last year Fibrobiologics made n/a in revenue.
what just happened
Latest quarter showed a -$0.39 EPS loss, with TTM revenue still at $0M.
At a glance
C+ balance sheet — struggling to keep the lights on
-$0.34 fy2024 eps est
~$21M market cap
small cap
NASDAQ
xvary composite: 23/100 — weak
What they do
It is a pre-revenue biotech trying to turn fibroblast cells into treatments for wounds, MS, spine disease, psoriasis, cancer, and aging.
The only visible edge is platform breadth. The company lists 6 named fibroblast programs, and it is trying to stretch one cell platform across six disease areas with just 13 employees, based on the company description. If that platform works, your upside comes from one science base feeding multiple shots on goal. If it does not, you are left with a $0 revenue biotech.
How they make money
n/a
annual revenue
The products that matter
treats diabetic foot ulcers
CYWC628
Phase 1/2 · interim results expected mid-2026
This is the lead program and the near-term reason the stock still exists as a public story. With $0 revenue today, any credible clinical signal here matters more than any income-statement line.
lead asset
targets disc degeneration
FSdC Spheroid Therapy
preclinical · positive animal data
This is earlier and riskier. It broadens the platform story, but preclinical data is not revenue, and it is not late-stage validation. For now, it is a reason to watch, not a reason to model sales.
preclinical
protects the platform
Patent Portfolio
270+ patents · $21M market cap
The patents are the balance-sheet story in narrative form. If a partner wants fibroblast IP, this matters. If no one does, you own a large filing cabinet attached to a small cash balance.
the real asset
Key numbers
$0M
ttm revenue
This matters because you are not valuing sales today. You are valuing trial outcomes and future financing.
-$0.34
fy2024 eps est
Losses are still the business model here. The primary source estimates a full-year loss of $0.34 a share for 2024.
$2M
long-term debt
Debt is only 8% of capital, but on a pre-revenue company every fixed obligation matters more.
13
employees
Deadpan fact bomb: 13 people are trying to advance six named therapy programs.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $2M (8% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for FBLG right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Latest quarter showed a -$0.39 EPS loss, with TTM revenue still at $0M.
This is what pre-revenue biotech looks like. The company is funding research, not collecting product sales, and the data sources show no reported revenue base to absorb ongoing losses.
$0M
revenue
-$0.39
eps
n/a
n/a
the number that mattered
The number that matters is $0M of TTM revenue, because every future quarter still depends more on financing and trial progress than on operations.
source: SEC filing data and market consensus, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The top risk here is running out of cash before the science has time to work. This is not a mature biotech debating margins. It is a $21M pre-revenue company trying to fund clinical progress and keep its Nasdaq listing at the same time.
med
cash runway
The company reported $4.9M in cash and a 2025 net loss of $18.6M. That is only a few months of operating cushion if spending stays near that pace.
The likely consequence is dilution. New capital may keep the company alive, but it can leave existing shareholders owning less of the same uncertain outcome.
med
Nasdaq compliance
FBLG received a delisting notice after the stock traded below $1 for 30 consecutive days. Management plans a reverse split to cure the listing problem.
If the stock fails to regain compliance, liquidity gets worse and many institutions become forced non-buyers. That matters more for a $21M microcap than for a large company.
med
clinical failure for CYWC628
The lead diabetic foot ulcer program is only in Phase 1/2, with interim results expected mid-2026. Early-stage cell therapy is where optimism goes to meet biology.
Bad or inconclusive data would directly damage the value of the lead asset, the patent story attached to it, and a stock already down 99% from its 52-week high.
med
patent value may stay theoretical
The company has 270+ patents, but patents only matter economically if they support a product, a licensing deal, or an acquisition conversation.
If no partner shows up and no program advances, the patent portfolio can remain intellectually interesting and financially irrelevant at the same time.
$4.9M of cash against a $18.6M annual loss implies roughly three months of runway at that pace. That puts financing risk in the foreground right now, not someday.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
CYWC628 interim data
Mid-2026 is the next real test. Positive early efficacy or safety signals could revive the platform story. Weak data would do the opposite.
cash
quarter-end cash balance
Start with the simple math: $4.9M in cash versus a $18.6M annual loss. If that gap is not shrinking, dilution pressure is not leaving.
listing
reverse split and Nasdaq status
A reverse split may restore compliance, but you should care more about what happens after it. Many microcaps split their way back above $1 and then drift lower anyway.
execution
partnering or licensing signals
With 270+ patents and no revenue, the cleanest outside validation would be a partner with money. Until then, the IP story is mostly management telling you it matters.
Analyst rankings
risk profile
high risk
risk rank 5 — significant risk of large drawdowns.
chart momentum
below average
momentum rank 4 — analysts see underperformance risk in the near term.
source: institutional data
Institutional activity
institutional ownership data for FBLG is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$0
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive